Fact vs. Fiction: Debunking common misconceptions about mobile visits

In this session, we’ll address five of the most common myths surrounding mobile visits, replacing assumptions with real-world data and operational insights:

  • Consistent clinician assignments build trust and strengthen patient relationships
  • Mobile visits can offer greater privacy and comfort than traditional sites
  • Decentralized models can accommodate complex protocols without compromising quality
  • Structured planning makes mobile visits logistically viable and scalable
  • Bringing research directly into communities expands access and improves retention and inclusivity

Navigating the complexities of site relationships: defining roles for sponsors and CROs

  • How sponsor and CRO priorities differ, and the importance of clearly defined roles in fostering effective site partnerships
  • Key distinctions between site engagement and site management, and how responsibilities should be strategically allocated
  • Opportunities for sponsors to strengthen site relationships through proactive engagement and thoughtful collaboration
  • Best practices for leveraging CRO networks and KOL partnerships to support site success, particularly in later-phase trials

Importance of effective vendor management in the clinical trial process through teamwork and clarity

  • Streamlining vendor management to reduce costs and timelines and to improve overall operational efficiency: Clear communication, defined roles and responsibilities and standardized documentation to enhance accessibility and collaboration
  • Mitigating risks associated with compliance, quality, and data integrity and reducing the impact of delays in patient recruitment, data collection, and regulatory submissions on trial budgets and timelines
  • Setting specific, measurable KPIs to evaluate vendor performance throughout the trial, focusing on metrics such as patient enrollment rates, data accuracy, and timeline adherence
  • Leverage technology for real-time monitoring of trial progress and vendor performance, allowing prompt identification of issues
  • Comprehensive evaluation of the closing out the trial process: Aligning goals, timelines and encouraging proactive management of timelines to identify potential bottlenecks early and involve vendors in the resolution process

PANEL DISCUSSION: Identifying patients as equal partners and including their voice in all stages of drug development

  • Acknowledging the value that patients can bring to every stage of the drug development pathway
  • Engaging patients and advocacy groups early on in the clinical trial design process
  • How minimizing participant burden leads to on-time enrollment and completion
  • Combining patient perspectives with those of healthcare professionals to create a holistic trial model
  • Highlighting how to compensate patients

Moderator: Amanda Murphy, Senior Director, Data Intelligence & Solutions, GlobalData